AZD 2811

Drug Profile

AZD 2811

Alternative Names: AZD 1152 HQPA; AZD2811

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca; BIND Therapeutics
  • Class Acetamides; Antineoplastics; Fluorobenzenes; Pyrazoles; Quinazolines
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Diffuse large B cell lymphoma; Lung cancer

Most Recent Events

  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
  • 04 Mar 2016 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Cancer released by BIND Therapeutics
  • 01 Oct 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (unspecified route) (NCT02579226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top